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Abstract 
Objective 
To determine risk of cardiovascular diseases (CVD), microvascular complications and mortality in 
patients with type 2 diabetes who subsequently develop obstructive sleep apnoea(OSA) compared 
to patients with type 2 diabetes without a diagnosis of OSA. 
Research Design and Methods 
An age-, sex-, body mass index- and diabetes duration-matched cohort study using data from a UK 
primary care database from 01/01/2005 to 17/01/2018. Participants aged ≥16 years with type 2 
diabetes were included. Exposed participants were those who developed OSA after their diabetes 
diagnosis; unexposed participants were those without diagnosed OSA. Outcomes were composite 
CVD (ischaemic heart disease(IHD), stroke/transient ischaemic attack(TIA), heart failure(HF)); 
peripheral vascular disease(PVD); atrial fibrillation(AF); peripheral neuropathy(PN); diabetes-related 
foot disease(DFD); referable retinopathy; chronic kidney disease(CKD); all-cause mortality. The same 
outcomes were explored in patients with pre-existing OSA before a diagnosis of type 2 diabetes 
versus diabetes without diagnosed OSA. 
Results 
3,667 exposed participants and 10,450 matched controls were included. Adjusted hazard ratios for 
the outcomes were: composite CVD 1.54(95%CI 1.32,1.79); IHD 1.55(1.26,1.90); HF 1.67(1.35,2.06); 
stroke/TIA 1.57(1.27,1.94); PVD 1.10(0.91,1.32); AF 1.53(1.28,1.83); PN 1.32(1.14,1.51); DFD 
1.42(1.16,1.74); retinopathy 0.99(0.82,1.21); CKD (stage 3-5) 1.18(1.02,1.36); albuminuria 
1.11(1.01,1.22); all-cause mortality 1.24(1.10,1.40). In the prevalent OSA cohort the results were 
similar but some associations not observed. 
Conclusions 
Patients with type 2 diabetes who develop OSA are at increased risk of CVD, AF, PN, DFD, CKD, and 
all-cause mortality compared to patients without diagnosed OSA. Patients with type 2 diabetes who 
develop OSA are a high-risk population and strategies to detect OSA and prevent cardiovascular and 
microvascular complications should be implemented. 
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Introduction 
Diabetes-related microvascular complications and cardiovascular disease (CVD) are major causes of 
morbidity, mortality and worsening quality of life in patients with type 2 diabetes.1,2,3 CVD 
prevention is one of the main aims of type 2 diabetes treatment.4 Improved health care delivery, 
including the use of lipid-lowering treatments, antiplatelets (for secondary prevention) and 
antihypertensives, has resulted in reduced mortality, CVD and vascular complications in patients 
with type 2 diabetes; however, the burden of these complications remains large due to the 
increasing prevalence of type 2 diabetes.4,5 Therefore, identifying risk factors and preventative 
strategies for the development of vascular disease and mortality in patients with type 2 diabetes are 
still needed.6 
Obstructive sleep apnoea (OSA) is common in patients with type 2 diabetes (24-86%) and patients 
with type 2 diabetes are at increased risk of developing OSA compared to patients without 
diabetes.7,8,9 Epidemiological studies in patients without diabetes showed that OSA was associated 
with increased risk of mortality and CVD (including stroke) which was improved with continuous 
positive airway pressure (CPAP) in non-randomised studies.10,11,12,13,14,15 Our group has previously 
shown a cross-sectional association between OSA and peripheral neuropathy (PN), sight threatening 
retinopathy, and chronic kidney disease (CKD) in patients with type 2 diabetes.8,16 We have also 
shown that OSA was associated with increased risk of renal function decline and development of 
CKD, and pre-proliferative/proliferative retinopathy in patients with type 2 diabetes in longitudinal 
studies.17,18,19 However, these studies were in a relatively small and were from secondary/tertiary 
care centres. The longitudinal associations between OSA and PN and diabetes-related foot disease 
(DFD) have not been explored previously. In addition, the relationship between OSA and incident 
CVD and mortality in patients with type 2 diabetes is largely unknown.  
We hypothesised that in patients with type 2 diabetes, the development of OSA increases the risk of 
CVD, microvascular complications and mortality. 
The primary aims of this study were to determine risk of incident CVD (ischaemic heart disease, 
stroke/transient ischaemic attack, or heart failure), PN, DFD, referable retinopathy, and CKD in 
patients with type 2 diabetes who go on to develop OSA compared to patients with type 2 diabetes 
but without diagnosed OSA. Secondary outcomes included the individual components of the 
composite CVD outcome; peripheral vascular disease (PVD); atrial fibrillation (AF); micro- and 
macroalbuminuria; and all-cause mortality. Additionally, in order to explore whether the sequence in 
which type 2 diabetes and OSA are diagnosed has any impact on observed outcomes, we conducted 
a second cohort study to determine risk of each of the outcomes in patients with type 2 diabetes 
and pre-existing OSA compared to patients with type 2 diabetes but without diagnosed OSA. 
Methods 
Study Design 
Age-, sex-, body mass index (BMI)- and diabetes duration-matched retrospective cohort study from 
1st January 2005 to 17th January 2018. 
Data Source 
The study dataset was extracted from The Health Improvement Network (THIN), a database 
comprising anonymised electronic primary care records for more than 15 million patients from 787 
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general practices across the UK. It contains coded information on patient demographics, symptoms, 
diagnoses, medication prescriptions, consultations, and diagnostic tests. The dataset is derived from 
routinely collected patient records and is generalizable to the UK population. THIN data has been 
used in numerous studies in the contexts of type 2 diabetes, OSA and cardiovascular disease.7,20,21,22  
Population 
General practices were included in the study from the latest of the following dates: 12 months after 
reporting acceptable mortality rates (a measure of data recording quality),23 12 months after starting 
to use electronic medical records, and study start date (1st January 2005). This was to maximise data 
and recording quality. 
Adults aged ≥16 years, registered with an eligible general practice for a minimum of 12 months, and 
with a record of type 2 diabetes were eligible for inclusion. Patients who underwent bariatric surgery 
or had a record of HIV at any time point were excluded. 
Primary Analysis: Incident OSA Exposure 
The exposed cohort comprised participants with type 2 diabetes and a subsequent, incident 
diagnosis of OSA (occurring after the diagnosis of type 2 diabetes and during the study period). Index 
(study entry) date for exposed patients was the date of OSA diagnosis.  
Each person in the exposed group was matched on index date to up to 4 randomly selected 
individuals with type 2 diabetes but without diagnosed OSA by age, sex, BMI and diabetes duration. 
Age and diabetes duration were matched to within ±1 year; BMI was matched to within ±2 kg/m2. 
Unexposed participants were assigned the same index date as their corresponding exposed 
participants in order to mitigate immortal time bias.24 The study design was an open cohort, 
therefore any individual with type 2 diabetes who developed incident OSA during the study period 
was included in the exposed cohort; as a result, no individuals in the unexposed population 
developed OSA during follow-up. 
Secondary Analysis: Prevalent OSA Exposure 
The exposed cohort comprised participants with incident type 2 diabetes (diagnosed during the 
study period) and prevalent OSA (occurring before the diagnosis of type 2 diabetes). Each exposed 
participant was matched to up to 4 randomly selected individuals with incident type 2 diabetes and 
no existing or subsequent diagnosis of OSA by age, sex, BMI (±2 kg/m2) and index year. Index date 
was the date of type 2 diabetes diagnosis for both exposed and unexposed participants. 
Follow-up Period 
Participants were followed up from the index date until the earliest of the following dates: outcome 
diagnosis, death, participant left the practice, the practice ceased contributing to the database, and 
study end (17th January 2018). 
Outcomes 
Primary outcomes were composite CVD (ischaemic heart disease (IHD), stroke or transient ischaemic 
attack (TIA) and heart failure (HF)); PN; DFD (defined as foot ulcer, lower limb amputation or 
gangrene of the foot); referable retinopathy (pre-proliferative (R2), proliferative (R3), maculopathy 
(M1), low vision/blindness, or corrective procedures for retinopathy such as laser and vitreous 
injections), and CKD stages 3-5. Secondary outcomes included each of the three composite CVD 
outcomes separately (IHD, stroke/TIA, HF); PVD; AF; albuminuria (albumin-creatinine ratio (ACR) >3 
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mg/mmol), macroalbuminuiria (ACR >30 mg/mmol), and severe macroalbuminuria (ACR >300 
mg/mmol); and all-cause mortality.  
Participants with a record of the outcome of interest at index date were excluded from the 
corresponding analysis, for example, for the composite CVD outcome, patients with a record of IHD, 
stroke/TIA or HF at baseline were excluded. In the analysis for PN as the outcome, participants with 
folate or B12 deficiency were excluded, as these deficiencies are associated with development of the 
outcome. 
Definitions of variables  
Type 2 diabetes was defined as a record of any diabetes clinical (Read) code and no record of type 1 
diabetes. Individuals with prevalent or incident (first recorded during the study period) diabetes 
were included. 
OSA, IHD, stroke/TIA, HF, PVD, AF, PN, DFD, referable retinopathy, hypertension and conditions 
contributing to the Charlson comorbidity index25 were defined by a record of a relevant diagnostic 
clinical (Read) code indicating presence of the condition. CKD stage 3-5 was defined by the presence 
of a relevant clinical code or by an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 
in two records separated by at least 90 days (the latter aligns with the definition used in clinical 
guidelines).26 All cardiovascular outcomes are included in the Quality and Outcomes Framework 
(QOF), a payment system which incentivises general practices in the UK to maintain disease 
registers;27 these outcomes are therefore well recorded in primary care. 
Covariates that might impact the outcomes were selected on the basis of biological plausibility and 
previous literature. Covariates included age; sex; BMI; Townsend deprivation quintile; smoking 
status; current prescription of lipid-lowering drugs, antihypertensives, antiplatelets, and insulin; 
ethnicity; diabetes duration; HbA1c; eGFR; ACR; hypertension; Charlson comorbidity index (CCI; 
mortality outcome only). 
Covariates were measured at baseline. Physiological measures were taken as the latest value 
recorded prior to index date. Current medication prescriptions were defined as those issued within 
60 days prior to the index date. Insulin prescription was used as an indication of disease severity. 
BMI was categorised as <25 kg/m2 (normal or underweight), 25-30 kg/m2 (overweight), and ≥30 
kg/m2 (obesity). Smoking was categorised as current smoker, ex-smoker and non-smoker. HbA1c 
was categorised as ≤47.5, 47.5-58.5, 58.5-69.4 and >69.4 mmol/mol. eGFR was calculated from 
serum creatinine values and ethnicity data (where available) using the CKD-EPI equation,28 and 
categorised as >60, 30-59 and <30 ml/min/1.73 m2. ACR was categorised as <3, 3-30 and >30 
mg/mmol.26 
Missing data 
Missing categories were used where values for BMI, smoking status, Townsend quintile, ethnicity, 
HbA1c, eGFR and ACR were not recorded. Implausible measurements of BMI, HbA1c, eGFR and ACR 
were considered data entry errors and were treated as missing. In a sensitivity analysis, missing 
values of BMI, HbA1c, eGFR and ACR were replaced using multiple imputation, using chained 
equations with predictive mean matching. The absence of a diagnostic code or medication code was 
taken to indicate absence of the condition or prescription, respectively. 
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Analysis 
Crude incidence rates (IR) were calculated for each outcome. Crude and adjusted hazard ratios (HR) 
and their corresponding 95% confidence intervals (CI) were calculated using Cox proportional 
hazards models. The proportional hazards assumption was checked using log-log plots and the 
Schoenfeld residuals test. Adjusted models for all cardiovascular outcomes (composite CVD, IHD, 
stroke/TIA, HF, PVD, AF) and microvascular diabetes complications (PN, DFD, referable retinopathy) 
included the following covariates measured at baseline: age category, sex, BMI category, smoking 
category, Townsend deprivation quintile, hypertension, prescription of lipid-lowering drugs, 
antihypertensives, antiplatelets and insulin, ethnicity, diabetes duration, HbA1c category, eGFR 
category, and ACR category. For renal outcomes (CKD, albuminuria), covariates were as above with 
the exclusion of eGFR and ACR, and with the addition of baseline cardiovascular disease (ischaemic 
heart disease, heart failure, stroke/transient ischaemic attack). The adjusted model for all-cause 
mortality outcome included: age, sex, BMI, smoking status, Townsend quintile, lipid-lowering drug 
prescription, antiplatelet prescription, antihypertensive prescription, insulin prescription, ethnicity, 
diabetes duration, HbA1c category, and CCI. 
In primary analysis, all identified exposed patients and their corresponding controls were included. It 
was not possible to identify matched controls for a small proportion of patients with OSA; therefore, 
sensitivity analyses were performed restricting to those exposed patients for whom one or more 
control was identified, together with the corresponding controls.   
All analyses were performed in Stata IC version 14. Two-sided p-values were obtained and p<0.05 
was considered statistically significant.   
Results 
Primary Analysis: Incident OSA Exposure 
In the primary analysis, we compared participants with type 2 diabetes and a subsequent diagnosis 
of OSA with participants with type 2 diabetes and no OSA. 3,667 adults with type 2 diabetes and a 
subsequent diagnosis of OSA and 10,450 controls with type 2 diabetes but no diagnosis of OSA were 
included in the analysis (Figure 1). Baseline characteristics are summarised in Table 1. The overall 
study population was middle age, mostly male, with a high prevalence of IHD (approximately one 
fifth) and hypertension (almost two thirds) at baseline, with the majority prescribed 
antihypertensives and lipid-lowering medications, and an average HbA1c of 7.5% (59 mmol/mol). 
Approximately 15% of the study population were current smokers. Age, sex, BMI and diabetes 
duration (matching parameters) were broadly similar between exposed and unexposed participants 
(Table 1). Compared to controls without diagnosed OSA, patients with type 2 diabetes who went on 
to develop OSA had marginally higher deprivation scores; were slightly more likely to be of South 
Asian ethnicity (3.0% compared to 2.2%); had a higher prevalence of hypertension and IHD; had a 
slightly higher mean HbA1c; and were more likely to be prescribed medications, particularly insulin 
(19.3% compared to 8.9%) at baseline (Table 1). 
Cardiovascular outcomes 
250 (10.1%) participants with type 2 diabetes and incident OSA and 564 (7.0%) controls with type 2 
diabetes and without diagnosed OSA developed composite CVD (IHD, stroke/TIA and HF) during 
follow-up (Supplementary Table 1). Median (IQR) follow-up was 3.1 (1.6-5.5) and 3.5 (1.7-5.9) years 
in exposed and unexposed patients. Crude IRs were 26.6 and 17.4 per 1000 person-years in exposed 
and unexposed participants, respectively. Crude and adjusted hazard ratios were 1.54 (95% CI 1.32, 
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1.78) and 1.54 (1.32, 1.79) respectively (Supplementary Table 1, Figure 2). These results suggest that 
incident OSA in patients with type 2 diabetes was associated with increased risk of incident 
composite CVD compared to patients with type 2 diabetes but without diagnosed OSA. 
Adjusted HRs for each of the component cardiovascular diseases were: IHD 1.55 (95% CI 1.26, 1.90); 
stroke/TIA 1.57 (1.27, 1.94); and HF 1.67 (1.35, 2.06) showing similar associations to those between 
OSA and composite CVD. 
For AF, adjusted HR was 1.53 (95% CI 1.28, 1.83). There was no statistically significant difference in 
hazard of PVD: adjusted HR 1.10 (0.91, 1.32; p=0.319). 
Diabetes-related microvascular outcomes 
For each of the microvascular outcomes, median follow-up period was approximately 3 years for 
exposed participants with type 2 diabetes and comorbid OSA and approximately 3.5 years for 
unexposed participants with type 2 diabetes but without diagnosed OSA. 
288 (10.5%) exposed participants and 697 (8.2%) unexposed participants developed peripheral 
neuropathy during follow-up (Supplementary Table 2). Hazard of peripheral neuropathy was 
significantly higher in participants with OSA compared to those without diagnosed OSA: crude 
hazard ratio was 1.37 (95% CI 1.19, 1.57); adjusted HR was 1.32 (1.14, 1.51) (Supplementary Table 2, 
Figure 3). 
161 (4.7%) and 289 (2.9%) exposed and unexposed participants, respectively, developed DFD. 
Hazard of DFD was significantly higher in participants with OSA compared to those without 
diagnosed OSA: crude and adjusted HRs were 1.76 (95% CI 1.45, 2.13) and 1.42 (1.16, 1.74), 
respectively. 
156 (4.7%) and 395 (4.0%) exposed and unexposed participants, respectively, developed diabetes-
related referable retinopathy. Crude HR was 1.22 (95% CI 1.01, 1.47); after adjustment for potential 
confounders, the result was not statistically significant: adjusted HR was 0.99 (0.82, 1.21; p=0.952). 
Renal outcomes 
276 (9.7%) exposed and 740 (8.6%) exposed and unexposed participants, respectively, developed 
CKD stage 3-5. There was a significant increase in hazard of CKD in the exposed group compared to 
the unexposed group: crude and adjusted HRs were 1.20 (95% CI 1.05, 1.38) and 1.18 (1.02, 1.36), 
respectively (Supplementary Table 2, Figure 3). 
Hazard of albuminuria was higher in participants with type 2 diabetes and incident OSA compared to 
those without diagnosed OSA, although this did not reach statistical significance for severe 
macroalbuminuria: adjusted HRs for micro/macroalbuminuria (ACR >3 mg/mmol), macroalbuminuria 
(ACR >30 mg/mmol) and severe macroalbuminuria (ACR >300 mg/mmol) were 1.11 (95% CI 1.01, 
1.22), 1.33 (1.13, 1.55) and 1.33 (0.92, 1.93), respectively. 
All-cause mortality 
434 (11.8%) exposed and 891 (8.5%) unexposed participants died during follow-up. Median (IQR) 
follow-up was 3.2 (1.7-5.8) and 3.6 (1.8-6.1) years in the exposed and comparator groups, 
respectively. Crude mortality rates were 29.9 and 20.3 per 1000 person-years in exposed and 
unexposed patients, respectively. Adjusted HR was 1.24 (95% CI 1.10, 1.40) (Supplementary Table 1, 
Figure 2), showing that OSA was associated with increased all-cause mortality in patents with type 2 
diabetes. 
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Sensitivity analysis 
A sensitivity analysis was performed excluding exposed participants with no matched controls; this 
made no difference to the observed findings (Supplementary Tables 1-3). A further supplementary 
analysis was performed replacing missing values by multiple imputation; this did not affect the 
results (Supplementary Tables 1-2). 
Prevalent OSA Exposure 
In secondary analysis, we explored outcomes in participants with incident type 2 diabetes and pre-
existing OSA (prevalent at the time of the type 2 diabetes diagnosis) compared to participants with 
type 2 diabetes and no OSA. 4,564 participants with type 2 diabetes and prevalent OSA and 15,589 
controls with diabetes and without diagnosed OSA were included in the analysis. Baseline 
characteristics are presented in Table 1. 
Cardiovascular outcomes 
Adjusted HRs for composite CVD, IHD, stroke/TIA and HF were 1.23 (95% CI 1.05, 1.43), 1.14 (0.95, 
1.38), 1.20 (0.94, 1.52), and 1.26 (0.98, 1.63), respectively (Supplementary Table 4, Figure 2). 
Adjusted HR for AF was 1.11 (0.91, 1.34) and for PVD 1.27 (1.17, 1.47). 
Microvascular outcomes 
Adjusted HRs for peripheral neuropathy, DFD and referable retinopathy were 1.22 (95% CI 1.11, 
1.34), 1.36 (1.08, 1.71), and 0.93 (0.75, 1.16), respectively (Supplementary Table 5, Figure 
3).Adjusted HRs for CKD (stage 3-5), micro/macroalbuminuria, macroalbuminuria and severe 
macroalbuminuria were 1.01 (95% CI 0.89, 1.15), 1.16 (1.09, 1.24), 1.21 (1.04, 1.41) and 1.37 (0.78, 
2.41), respectively (Supplementary Table 5, Figure 3). 
All-cause mortality 
Adjusted HR for all-cause mortality was 1.00 (95% CI 0.88-1.14) (Supplementary Table 4, Figure 2) 
Discussion 
In this cohort study, participants who developed OSA after their diagnosis of type 2 diabetes had a 
more than 50% increase in risk of composite CVD, IHD, HF and stroke/TIA, a 53% greater risk of 
developing AF, a 32% increase in risk of peripheral neuropathy, a 42% increase in risk of DFD, an 18% 
increase in risk of CKD stages 3-5, an 11% increased risk of albuminuria, and a 24% increase in risk of 
all-cause mortality compared to participants with type 2 diabetes and no OSA. These results were 
observed after matching for age, sex, BMI and diabetes duration, and adjusting for a range of 
potential confounders. There were no significant associations between OSA and the risk of PVD or 
referable retinopathy in this study. 
This study adds novel insights and findings to the limited published literature describing the impact 
of OSA on cardiovascular outcomes in patients with type 2 diabetes. A previous study showed an 
association between OSA and stroke; however, this was cross-sectional, relied on self-reported 
outcomes and was of small sample size.29. Two previously published cohort studies showed an 
association between OSA and CVD/mortality,30,31,32 but these studies were in highly selected 
populations (patients with type 2 diabetes referred to cardiology units for the investigation of 
coronary artery disease in one study, and patients referred for percutaneous coronary intervention 
in the other). In addition, these studies were of smaller sample size, the analysis adjusted for a 
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limited number of variables, and one of the studies included people at high risk of OSA rather than 
diagnosed OSA. 
Hence, our study provides significant findings and adds methodological rigour compared to the 
limited published literature in that it was a population-based study of large sample size, allowing for 
adjustment for a large number of potential confounders, and examined the association between 
OSA and multiple individual CVD outcomes, as well as all-cause mortality and microvascular 
complications, in patients with type 2 diabetes. 
The association of OSA with incident AF in our study was mirrored by a similar association with 
incident stroke. Hence, our data suggest that identifying patients with type 2 diabetes who have OSA 
might provide an opportunity to examine for AF and implement appropriate stroke prevention 
strategies. There is interest in the impact of OSA in AF patients on the risk of stroke and AF 
recurrence following ablation.33,34 
Our study also shows that having OSA identifies a high-risk population with type 2 diabetes in which 
CVD-prevention measures should be maximised. To our knowledge, our study is the first to report 
the association between OSA and mortality in patients with type 2 diabetes, which is similar to that 
observed in general population studies without diabetes.12,13,15 
Our study is the first to show the relationship between OSA and PN and DFD in patients with type 2 
diabetes in a longitudinal, population-based study. We have previously shown an association 
between OSA and PN in a cross-sectional study.16 We have also previously shown OSA to be 
associated with CKD in a cross-sectional analysis, and with eGFR decline in a longitudinal study, in 
secondary/tertiary care centres in the UK.19,35 The current study allowed us to expand our findings to 
a more representative population and to examine the impact of OSA on albuminuria. Unlike our 
previous longitudinal study that showed an association between OSA and increased risk of pre-
proliferative and proliferative retinopathy,17 this study showed no significant association between 
OSA and referable retinopathy after adjustment. This difference may be explained by the different 
study populations – secondary/tertiary vs primary care – and the use of a broader outcome measure 
(referable retinopathy) compared to our previous study, which was based only on the development 
of R2 or R3. 
There are multiple mechanisms that link OSA to CVD and microvascular complications including 
insulin resistance, hypertension, increased oxidative and nitrosative stress, sympathetic activation, 
increased inflammation and endothelial dysfunction, which can improve with CPAP.35,36 Our findings 
pose the question whether CPAP should form part of CVD and mortality prevention in patients with 
type 2 diabetes and comorbid OSA. Our study does not address this question, but despite 
observational studies showing an association between use of CPAP and vascular benefits in patients 
with OSA, data from RCTs remains lacking,37,38 with the exception of one RCT that showed CPAP 
reduced cardiovascular events and mortality after first ischaemic stroke.11 However, CPAP trials are 
always challenging due to the lack of adherence to treatment. Nonetheless, the impact of CPAP on 
cardiovascular disease in patients with type 2 diabetes needs to be assessed in well-designed RCTs. 
In the secondary analysis exploring outcomes in participants with type 2 diabetes and prevalent OSA 
compared to type 2 diabetes only, participants with OSA continued to be at increased risk of 
composite CVD, peripheral neuropathy, DFD and albuminuria. The association between OSA and 
increased risk of individual components of the composite CVD outcome, AF, CKD, and all-cause 
mortality was no longer significant. This secondary analysis included participants with 
incident/newly diagnosed type 2 diabetes; the difference in findings is therefore likely to be driven 
by the fact that these individuals had had type 2 diabetes for a shorter period of time at the end of 
10 
 
follow-up compared to the primary analysis cohort (which included participants with prevalent 
diabetes). Another possible reason is that patients in the prevalent OSA group might have received 
better vascular prevention compared to the control group prior to the incident diagnosis of type 2 
diabetes. 
Strengths and Limitations 
Routinely collected data may be subject to incorrect, inconsistent or incomplete recording. However, 
type 2 diabetes, cardiovascular diseases and CKD are part of the UK QOF which is linked to practice 
funding, and recording quality is therefore expected to be high. The QOF indicator set for diabetes 
includes requirements to measure and record smoking status, BMI, blood pressure, HbA1c, ACR and 
serum creatinine, as well as to perform and record annual foot assessments and retinal screening; 
this information is therefore likely to be well recorded for patients included in the cohort. After 
adjusting for patient demographics, the prevalence of major chronic diseases and death rates in 
THIN are similar to national rates.39 
Ethnicity is poorly recorded in THIN and was therefore not available for all patients in the cohort. 
Previous analysis has shown that the prevalence of OSA in THIN may be lower than expected rates 
based on existing literature, suggesting that OSA may be underdiagnosed or underreported in UK 
primary care data;7 it is possible, therefore, that patients diagnosed with OSA in routine care 
represent a more severe or symptomatic phenotype and hence our results may not be 
representative of all patients with type 2 diabetes and OSA. Underdiagnosis of OSA in primary care 
may have resulted in patients with undiagnosed OSA being included in the unexposed group, leading 
to an underestimation of the strength of the observed associations. 
The presence of detection bias cannot be completely ruled out; however, we think it is unlikely to 
have had a major impact. All patients with type 2 diabetes are reviewed at least annually in England 
and assessed for vascular complications as part of the QOF; therefore, surveillance bias is unlikely to 
have had a major impact on our results. This is supported by the lack of increased risk of 
retinopathy, and by evidence from previous studies in which screen-detected OSA was associated 
with vascular complications in patients with type 2 diabetes. 
The study included a large sample size from a dataset which is generalizable to the UK population. 
This is the first population-based cohort study to assess the association of OSA diagnosed after type 
2 diabetes with cardiovascular endpoints, including composite CVD, AF, IHD, stroke/TIA and heart 
failure, and with microvascular and renal outcomes. The large sample size and characterisation of 
the study population allowed us to adjust for a large number of variables that might affect the 
associations between OSA and CVD in patients with type 2 diabetes. In addition, the matching design 
further strengthened the methodology of our study.  
Conclusion 
Patients with type 2 diabetes who go on to develop comorbid OSA are at increased risk of incident 
CVD, including IHD, stroke/TIA and heart failure, and AF, as well as increased risk of PN, DFD, CKD, 
albuminuria and all-cause mortality. Physicians need to recognise that patients with type 2 diabetes 
who develop OSA are a high-risk population and strategies to detect OSA and prevent vascular 
complications should be implemented. RCTs examining the impact of CPAP on cardiovascular and 
microvascular outcomes in patients with OSA and type 2 diabetes are needed.  
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Table 1. Baseline characteristics of study participants  
Participant characteristic 
Primary analysis: 
Incident OSA 
Secondary analysis: 
Prevalent OSA 
 Exposed Unexposed Exposed Unexposed 
Population, n 3,667 10,450 4,564 15,589 
Age (years), mean (SD)† 60.07 (10.56) 60.99 (9.08) 57.14 (11.04) 57.60 (10.89) 
Age at diagnosis of T2DM (years), mean (SD) 53.12 (10.33) 54.95 (8.71) 57.14 (11.04) 57.60 (10.89) 
Age at diagnosis of OSA (years), mean (SD) 60.07 (10.56) - 51.51 (11.12) - 
T2DM to OSA development time (years), mean (SD) 6.95 (6.18) - - - 
OSA to T2DM development time (years), mean (SD) - - 5.63 (4.80) - 
T2DM duration (years), mean (SD)† 6.95 (6.18) 6.04 (4.94)   
Sex, n (%)†     
Male 2679 (73.06) 7914 (75.73) 3558 (77.96) 12062 (77.38) 
Female 988 (26.94) 2536 (24.27) 1006 (22.04) 3527 (22.62) 
BMI (kg/m2), mean (SD)† 37.68 (7.65) 35.70 (6.00) 38.27 (7.94) 36.89 (6.95) 
BMI categories, n (%)     
Underweight (< 25 kg/m2) 56 (1.53) 183 (1.75) 60 (1.31) 243 (1.56) 
Overweight (25 - 30 kg/m2) 356 (9.71) 1431 (13.69) 494 (10.82) 2050 (13.15) 
Obese (> 30 kg/m2) 3216 (87.70) 8828 (84.48) 3898 (85.41) 12871 (82.56) 
Missing 39 (1.06) 8 (0.08) 112 (2.45) 425 (2.73) 
Smoking status, n (%)     
Non-smoker 1489 (40.61) 4548 (43.52) 1815 (39.77) 6846 (43.92) 
Ex-smoker 1588 (43.31) 4284 (41.00) 1835 (40.21) 5690 (36.50) 
Smoker 589 (16.06) 1608 (15.39) 903 (19.79) 2988 (19.17) 
Missing 1 (0.03) 10 (0.10) 11 (0.24) 65 (0.42) 
Ethnicity, n (%)     
White 1774 (48.38) 4939 (47.26) 2215 (48.53) 7473 (47.94) 
Black Afro-Caribbean 39 (1.06) 154 (1.47) 59 (1.29) 213 (1.37) 
Chinese 10 (0.27) 25 (0.24) 8 (0.18) 29 (0.19) 
South Asian 109 (2.97) 230 (2.20) 91 (1.99) 344 (2.21) 
Mixed race 15 (0.41) 42 (0.40) 31 (0.68) 82 (0.53) 
Missing 1720 (46.90) 5060 (48.42) 2160 (47.33) 7448 (47.78) 
Townsend deprivation quintile, n (%)     
1 (least deprived) 637 (17.37) 1868 (17.88) 768 (16.83) 2651 (17.01) 
2 606 (16.53) 1854 (17.74) 818 (17.92) 2698 (17.31) 
3 696 (18.98) 2003 (19.17) 896 (19.63) 2987 (19.16) 
4 692 (18.87) 1857 (17.77) 816 (17.88) 2823 (18.11) 
5 (most deprived) 555 (15.13) 1452 (13.89) 633 (13.87) 2265 (14.53) 
Missing 481 (13.12) 1416 (13.55) 633 (13.87) 2165 (13.89) 
HbA1c (mmol/mol), mean (SD) 59.82 (17.03) 58.37 (16.78) 62.39 (21.13) 63.98 (21.76) 
HbA1c category, n (%)     
≤ 47.5 mmol/mol 699 (19.06) 2169 (20.76) 398 (8.72) 1303 (8.36) 
47.5 - 58.5 mmol/mol 1123 (30.62) 3321 (31.78) 1268 (27.78) 3744 (24.02) 
58.5 - 69.4 mmol/mol 598 (16.31) 1462 (13.99) 366 (8.02) 1235 (7.92) 
> 69.4 mmol/mol 680 (18.54) 1681 (16.09) 659 (14.44) 2498 (16.02) 
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Missing 567 (15.46) 1817 (17.39) 1873 (41.04) 6809 (43.68) 
eGFR (ml/min per 1.73 m2), mean (SD) 79.33 (22.57) 81.42 (19.10) 85.40 (18.26) 85.03 (18.18) 
eGFR category, n (%)     
> 60 ml/min per 1.73 m2 (stage 2 and below) 2913 (79.44) 8808 (84.29) 3997 (87.58) 13393 (85.91) 
30-59 ml/min per 1.73 m2 (stage 3) 568 (15.49) 1223 (11.70) 350 (7.67) 1175 (7.54) 
< 30 ml/min per 1.73 m2 (stage 4-5) 99 (2.70) 101 (0.97) 12 (0.26) 57 (0.37) 
Missing 87 (2.37) 318 (3.04) 205 (4.49) 964 (6.18) 
Albumin creatinine ratio (mg/mmol), mean (SD) 11.47 (48.72) 6.16 (26.04) 6.99 (20.24) 7.47 (29.75) 
Albumin creatinine ratio category, n (%)     
< 3 mg/mmol 1479 (40.33) 4791 (45.85) 388 (8.50) 1366 (8.76) 
3.0 - 30.0 mg/mmol 582 (15.87) 1293 (12.37) 172 (3.77) 507 (3.25) 
> 30 mg/mmol 166 (4.53) 243 (2.33) 32 (0.70) 87 (0.56) 
Missing 1440 (39.27) 4123 (39.45) 3972 (87.03) 13629 (87.43) 
Baseline cardiovascular conditions, n (%)     
Heart failure 336 (9.16) 377 (3.61) 226 (4.95) 437 (2.80) 
Ischaemic heart disease 867 (23.64) 1836 (17.57) 765 (16.76) 2037 (13.07) 
Stroke/TIA 307 (8.37) 665 (6.36) 257 (5.63) 729 (4.68) 
Peripheral vascular disease 607 (16.55) 1189 (11.38) 106 (2.32) 366 (2.35) 
Atrial fibrillation 375 (10.23) 623 (5.96) 339 (7.43) 780 (5.00) 
Hypertension 2451 (66.84) 6615 (63.30) 2376 (52.06) 7699 (49.39) 
Baseline microvascular conditions, n (%)     
Peripheral neuropathy 921 (25.12) 1997 (19.11) 81 (1.77) 161 (1.03) 
Diabetes-related foot disease 247 (6.74) 427 (4.09) 147 (3.22) 349 (2.24) 
Referable retinopathy 320 (8.73) 699 (6.69) 91 (1.99) 194 (1.24) 
CKD stage 3-5 828 (22.58) 1856 (17.76) 551 (12.07) 1645 (10.55) 
Micro-macroalbuminuria 1391 (37.93) 3209 (30.71) 296 (6.49) 823 (5.28) 
Macroalbuminuria 347 (9.46) 555 (5.31) 66 (1.45) 148 (0.95) 
Sever macroalbuminuria 26 (0.71) 33 (0.32) 5 (0.11) 17 (0.11) 
Baseline drug use (within 60 days of index), n (%)     
Lipid-lowering drugs 2628 (71.67) 7267 (69.54) 1963 (43.01) 6381 (40.93) 
Antihypertensives 2911 (79.38) 7600 (72.73) 2808 (61.52) 8941 (57.35) 
Antiplatelets 1439 (39.24) 3616 (34.60) 1040 (22.79) 2953 (18.94) 
Insulin 708 (19.31) 930 (8.90) 16 (0.35) 42 (0.27) 
Charlson comorbidity index, n (%)     
1 1184 (32.29) 4511 (43.17) 2202 (48.25) 9234 (59.23) 
2 1199 (32.70) 3330 (31.87) 1448 (31.73) 4004 (25.68) 
3 664 (18.11) 1481 (14.17) 543 (11.90) 1463 (9.38) 
≥4 620 (16.91) 1128 (10.79) 371 (8.13) 888 (5.70) 
 
†Matching parameters. T2DM = type 2 diabetes; BMI = body mass index; eGFR = estimated 
glomerular filtration rate. 
  
13 
 
Figures 
 
Figure 1. Flow diagram summarising numbers of included participants in the incident OSA analysis. 
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Figure 2. Forest plot showing adjusted hazard ratios for each of the cardiovascular and mortality 
outcomes assessed, for both incident and prevalent OSA exposure. 
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Figure 3. Forest plot showing adjusted hazard ratios for each of the microvascular outcomes 
assessed, for both incident and prevalent OSA exposure. 
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